Our dedication to advancing technology and making tangible differences in healthcare is unwavering. Partnering with Jacobio Pharmaceuticals offers a unique opportunity to collaborate on groundbreaking initiatives…
In Conversation
Our aim is not to become as large as the IQVIAs or Parexels of this world, but to remain a mid-sized CRO that is as global…
We want to be the prime example of an innovative, science-driven biotech from China, showcasing the best of world capability in terms of innovation, rather than…
Our intention is to become a China-based international company that leads in the genomics space globally
BioDuro has very strong capabilities on the discovery side and has a significant presence in both China and the US. Meanwhile, Sundia is extremely strong in…
The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer and some types of autoimmune diseases are well-known for…
Despite the fact that I joined the company during the peak of the COVID-19 epidemic in China, we have achieved a number of milestones in the…
We believe, to make a meaningful impact on treatment, it is necessary to have more than one drug or regimen. We therefore see combination therapies as…
Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers in this area
Fundamentally, we are convinced that the China ophthalmology market is still a relatively blank slate with huge potential for innovative therapies and drugs, compared to the…
By now, we have a platform of over 500 billion small molecules, and in terms of published numbers, we probably have the largest DEL collections in…
From an R&D perspective ... what is critical in ophthalmology is the development of a novel drug delivery mechanism
